Literature DB >> 17525905

Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia.

A Tröger1, M Siepermann, C Mahotka, N Wethkamp, H Bülle, H-J Laws, G Escherich, G Janka-Schaub, U Göbel, D Dilloo.   

Abstract

BACKGROUND: Survivin, a member of the inhibitor of apoptosis protein (IAP) family is transiently expressed at low levels during normal hematopoesis but profoundly overexpressed in adult leukemia potentially contributing to leukemogenesis due to deregulated apoptosis and defective cell cycle control. Alternative splicing results in four different mRNA variants survivin, survivin2B, survivin-DeltaExon3 and survivin-3B, with distinct cellular localization patterns and anti-apoptotic potential. Due to co-localization of survivin and survivin-2B in the cytoplasm survivin-2B may permit interactive fine-tuning of survivin actions and moreover play an attenuating role in its anti-apoptotic function. Lack of survivin-2B is associated with disease progression of malignomas suggesting a differential role of these isoforms in tumorigenesis. PATIENTS AND METHODS: We therefore determined the expression of the functional survivin splice variants performing RT- and real-time PCR in a purely pediatric cohort of 20 patients suffering from precursor B-ALL (BCP-ALL).
RESULTS: Here, we demonstrate for the first time in pediatric patients with precursor B-ALL an association between lower survivin-2B expression and affiliation to the high risk group.
CONCLUSION: The idea that survivin-2B may act as natural antagonist of survivin could potentially be used in novel approaches of anti-cancer treatment by influencing the proportional expression of the different splice variants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525905     DOI: 10.1055/s-2007-973850

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  5 in total

Review 1.  Clinico-pathologic relevance of Survivin splice variant expression in cancer.

Authors:  Rosalia de Necochea-Campion; Chien-Shing Chen; Saied Mirshahidi; Frank D Howard; Nathan R Wall
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

Review 2.  Monitoring survivin expression in cancer: implications for prognosis and therapy.

Authors:  Rodrigo Santa Cruz Guindalini; Maria Cecília Mathias Machado; Bernardo Garicochea
Journal:  Mol Diagn Ther       Date:  2013-12       Impact factor: 4.074

Review 3.  Nanopreparations to overcome multidrug resistance in cancer.

Authors:  Niravkumar R Patel; Bhushan S Pattni; Abraham H Abouzeid; Vladimir P Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2013-08-23       Impact factor: 15.470

4.  How to target apoptosis signaling pathways for the treatment of pediatric cancers.

Authors:  Simone Fulda
Journal:  Front Oncol       Date:  2013-02-14       Impact factor: 6.244

Review 5.  Inhibitor of apoptosis proteins in pediatric leukemia: molecular pathways and novel approaches to therapy.

Authors:  Simone Fulda
Journal:  Front Oncol       Date:  2014-01-27       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.